Nantong Jinghua Pharmaceutical Co Ltd (002349) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.032x

Based on the latest financial reports, Nantong Jinghua Pharmaceutical Co Ltd (002349) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥97.93 Million ≈ $14.33 Million USD) by net assets (CN¥3.09 Billion ≈ $452.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Nantong Jinghua Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Nantong Jinghua Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 002349 total liabilities for a breakdown of total debt and financial obligations.

Nantong Jinghua Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nantong Jinghua Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Friend Co Ltd
SHG:605050
N/A
Joeone Co Ltd
SHG:601566
0.013x
Tianjin Printronics Circuit Corp
SHE:002134
0.067x
Astra Agro Lestari Tbk
JK:AALI
0.063x
Shenzhen Bingchuan Network Co Ltd
SHE:300533
0.009x
EQ Resources Ltd
AU:EQR
-0.169x
Sdiptech AB (publ)
ST:SDIP-B
0.080x
Neto Malinda
TA:NTML
-0.058x

Annual Cash Flow Conversion Efficiency for Nantong Jinghua Pharmaceutical Co Ltd (2006–2024)

The table below shows the annual cash flow conversion efficiency of Nantong Jinghua Pharmaceutical Co Ltd from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Nantong Jinghua Pharmaceutical Co Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥2.96 Billion
≈ $432.72 Million
CN¥311.02 Million
≈ $45.51 Million
0.105x +1.25%
2023-12-31 CN¥2.80 Billion
≈ $410.35 Million
CN¥291.31 Million
≈ $42.63 Million
0.104x -23.95%
2022-12-31 CN¥2.62 Billion
≈ $383.94 Million
CN¥358.39 Million
≈ $52.44 Million
0.137x +14.86%
2021-12-31 CN¥2.57 Billion
≈ $376.01 Million
CN¥305.57 Million
≈ $44.71 Million
0.119x -9.90%
2020-12-31 CN¥2.49 Billion
≈ $363.89 Million
CN¥328.22 Million
≈ $48.03 Million
0.132x -0.67%
2019-12-31 CN¥2.15 Billion
≈ $314.28 Million
CN¥285.38 Million
≈ $41.76 Million
0.133x +329.14%
2018-12-31 CN¥2.69 Billion
≈ $394.28 Million
CN¥83.43 Million
≈ $12.21 Million
0.031x +7.96%
2017-12-31 CN¥2.65 Billion
≈ $387.36 Million
CN¥75.92 Million
≈ $11.11 Million
0.029x -80.79%
2016-12-31 CN¥2.30 Billion
≈ $336.95 Million
CN¥343.80 Million
≈ $50.31 Million
0.149x +538.78%
2015-12-31 CN¥2.23 Billion
≈ $326.88 Million
CN¥-76.01 Million
≈ $-11.12 Million
-0.034x -214.26%
2014-12-31 CN¥1.53 Billion
≈ $224.56 Million
CN¥45.70 Million
≈ $6.69 Million
0.030x +140.21%
2013-12-31 CN¥741.83 Million
≈ $108.55 Million
CN¥-54.94 Million
≈ $-8.04 Million
-0.074x -168.54%
2012-12-31 CN¥714.87 Million
≈ $104.61 Million
CN¥77.25 Million
≈ $11.30 Million
0.108x +65.90%
2011-12-31 CN¥636.30 Million
≈ $93.11 Million
CN¥41.45 Million
≈ $6.06 Million
0.065x -13.63%
2010-12-31 CN¥544.45 Million
≈ $79.67 Million
CN¥41.06 Million
≈ $6.01 Million
0.075x -82.10%
2009-12-31 CN¥137.11 Million
≈ $20.06 Million
CN¥57.76 Million
≈ $8.45 Million
0.421x +191.81%
2008-12-31 CN¥118.66 Million
≈ $17.36 Million
CN¥17.13 Million
≈ $2.51 Million
0.144x -60.84%
2007-12-31 CN¥91.86 Million
≈ $13.44 Million
CN¥33.86 Million
≈ $4.96 Million
0.369x +16.34%
2006-12-31 CN¥70.00 Million
≈ $10.24 Million
CN¥22.18 Million
≈ $3.25 Million
0.317x --

About Nantong Jinghua Pharmaceutical Co Ltd

SHE:002349 China Drug Manufacturers - Specialty & Generic
Market Cap
$912.98 Million
CN¥6.24 Billion CNY
Market Cap Rank
#9510 Global
#2637 in China
Share Price
CN¥7.52
Change (1 day)
+2.87%
52-Week Range
CN¥6.78 - CN¥8.28
All Time High
CN¥25.53
About

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and… Read more